Evidence map›Paper›PMID 33718163›Full record

ArticleFrontiers in oncology2021

High Nuclear Expression of Yes-Associated Protein 1 Correlates With Metastasis in Patients With Breast Cancer.

Yoon Jin Cha, Soong June Bae, Dooreh Kim, Sung Gwe Ahn, Joon Jeong, Ja Seung Koo, Tae-Kyung Yoo, Woo-Chan Park, Ahwon Lee, Chang Ik Yoon

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Hippo-TAZ signaling is the master regulator of the onset of triple-negative basal-like breast cancers.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Yoon Jin ChaDepartment of Pathology, Gangnam Severance Hospital, College of Medicine, Yonsei University, Seoul, South Korea.
Soong June BaeDepartment of Surgery, Gangnam Severance Hospital, College of Medicine, Yonsei University, Seoul, South Korea.
Dooreh KimDepartment of Surgery, Gangnam Severance Hospital, College of Medicine, Yonsei University, Seoul, South Korea.
Sung Gwe AhnDepartment of Surgery, Gangnam Severance Hospital, College of Medicine, Yonsei University, Seoul, South Korea.
Joon JeongDepartment of Surgery, Gangnam Severance Hospital, College of Medicine, Yonsei University, Seoul, South Korea.
Ja Seung KooDepartment of Pathology, Severance Hospital, College of Medicine, Yonsei University, Seoul, South Korea.
Tae-Kyung YooDivision of Breast Surgery, Department of Surgery, College of Medicine, Seoul St Mary's Hospital, The Catholic University of Seoul, Seoul, South Korea.
Woo-Chan ParkDivision of Breast Surgery, Department of Surgery, College of Medicine, Seoul St Mary's Hospital, The Catholic University of Seoul, Seoul, South Korea.
Ahwon LeeDepartment of Pathology, Seoul St Mary's Hospital, College of Medicine, The Catholic University of Seoul, Seoul, South Korea.
Chang Ik YoonDivision of Breast Surgery, Department of Surgery, College of Medicine, Seoul St Mary's Hospital, The Catholic University of Seoul, Seoul, South Korea.
Gangnam Severance Hospital · KRThe Catholic University of Korea Seoul St. Mary's Hospital · KRYonsei University · KRUniversity of Seoul · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundYes-associated protein 1 (YAP1) is a transcription factor regulated by the Hippo pathway and functions as an oncogene in various solid tumors under dysregulated Hippo pathway. However, the role of YAP1 in breast cancer remains controversial. Here, we investigated the impact of different levels of nuclear YAP1 expression on the clinical characteristics and survival outcome in patients with breast cancer. PATIENTS AND

methodsRetrospectively obtained 455 breast tumor samples at Gangnam Severance Hospital were examined for YAP1 expression by immunohistochemistry, and the clinical data were analyzed. External validation was performed using a retrospective cohort and tissues in 482 patients from Severance Hospital.

resultsHigh nuclear YAP1 expression was associated with hormone receptor negativity and aggressive tumor behavior, including lymph node metastasis, high Ki67 labeling index and inferior distant metastasis-free survival (DMFS, hazard ratio [HR] 2.271, 95% confidence intervals [CIs] 1.109-4.650,

conclusionOur findings suggest that nuclear YAP1 expression is a biomarker of adverse prognosis and a potential therapeutic target in patients with breast cancer, especially in TNBC.

Indexed as

breast cancermetastasisprognosistriple-negative breast cancerYes-associated protein 1

Identifiers

PMID33718163
PMCPMC7947190
OpenAlexW3132182479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.